What is HC Wainwright’s Estimate for RIGL Q1 Earnings?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Rigel Pharmaceuticals in a research report issued on Wednesday, March 5th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will post earnings per share of ($0.07) for the quarter. HC Wainwright currently has a “Buy” rating and a $57.00 price target on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ Q2 2025 earnings at $0.12 EPS, FY2025 earnings at $0.88 EPS and FY2026 earnings at $2.08 EPS.

A number of other analysts have also recently issued reports on the company. B. Riley raised their price objective on Rigel Pharmaceuticals from $20.00 to $24.00 and gave the company a “neutral” rating in a research report on Wednesday. Citigroup increased their price target on shares of Rigel Pharmaceuticals from $49.00 to $55.00 and gave the company a “buy” rating in a report on Thursday. Piper Sandler increased their price target on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the company a “neutral” rating in a report on Thursday, November 14th. StockNews.com cut shares of Rigel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. Finally, Cantor Fitzgerald upped their price target on shares of Rigel Pharmaceuticals from $15.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday, December 10th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.80.

Rigel Pharmaceuticals Stock Up 4.2 %

RIGL opened at $20.52 on Friday. Rigel Pharmaceuticals has a 12-month low of $7.48 and a 12-month high of $29.82. The stock has a market cap of $361.46 million, a price-to-earnings ratio of 146.58 and a beta of 1.35. The business has a 50 day moving average of $20.14 and a 200-day moving average of $18.43.

Rigel Pharmaceuticals (NASDAQ:RIGL) last released its quarterly earnings data on Tuesday, March 4th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.50. Rigel Pharmaceuticals had a negative return on equity of 14.80% and a net margin of 2.46%. The company had revenue of $57.60 million during the quarter, compared to analysts’ expectations of $57.59 million.

Insider Transactions at Rigel Pharmaceuticals

In related news, EVP David A. Santos sold 2,125 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $20.92, for a total transaction of $44,455.00. Following the completion of the transaction, the executive vice president now directly owns 53,500 shares in the company, valued at $1,119,220. This represents a 3.82 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Raul R. Rodriguez sold 4,952 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $20.92, for a total transaction of $103,595.84. Following the transaction, the chief executive officer now owns 243,854 shares of the company’s stock, valued at approximately $5,101,425.68. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,113 shares of company stock valued at $190,644. 9.04% of the stock is owned by corporate insiders.

Institutional Trading of Rigel Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in RIGL. Los Angeles Capital Management LLC grew its holdings in shares of Rigel Pharmaceuticals by 34.5% during the third quarter. Los Angeles Capital Management LLC now owns 74,502 shares of the biotechnology company’s stock worth $1,205,000 after purchasing an additional 19,094 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Rigel Pharmaceuticals by 29.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 98,006 shares of the biotechnology company’s stock worth $1,586,000 after buying an additional 22,443 shares during the period. FMR LLC grew its position in shares of Rigel Pharmaceuticals by 119.4% in the 3rd quarter. FMR LLC now owns 48,105 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 26,184 shares during the last quarter. BNP Paribas Financial Markets increased its stake in shares of Rigel Pharmaceuticals by 1,199.2% in the third quarter. BNP Paribas Financial Markets now owns 21,008 shares of the biotechnology company’s stock valued at $340,000 after buying an additional 19,391 shares during the period. Finally, Stonepine Capital Management LLC raised its position in shares of Rigel Pharmaceuticals by 1.3% during the third quarter. Stonepine Capital Management LLC now owns 309,100 shares of the biotechnology company’s stock worth $5,001,000 after acquiring an additional 4,100 shares during the last quarter. 66.23% of the stock is currently owned by institutional investors.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.